Epidemiological, Clinicopathological, and Surgical Characteristics of Eyelid Carcinomas (epidemiology)

July 19, 2026 updated by: Younes Oujidi, Mohammed VI University Hospital

Epidemiological, Clinicopathological, and Surgical Characteristics of Eyelid Carcinomas: A Three-Year Retrospective Case Series From Eastern Morocco

Twenty patients were included, comprising 11 women (55%) and 9 men (45%), with a mean age of 63.1 years. Chronic sun exposure was identified in 18 patients (90%). The lower eyelid was the most commonly affected site in 9 cases (45%). Basal cell carcinoma accounted for 15 tumors (75%), followed by squamous cell carcinoma in 5 cases (25%). Wide local excision with histopathological margin control was performed in all patients (20/20, 100%), and orbital exenteration was required in 1 case (5%). Reconstruction was achieved mainly using local flaps in 12 patients (60%). Ectropion occurred in 2 patients (10%). No local recurrence was observed during a mean follow-up of 22 months.

Study Overview

Status

Completed

Conditions

Detailed Description

This retrospective study was conducted over a three-year period, from January 2023 to December 2025, and included 20 patients with eyelid carcinomas who underwent surgical treatment in the Department of Plastic and Reconstructive Surgery at Mohammed VI University Hospital. Demographic, clinical, histological, therapeutic, and outcome data were analyzed.

Study Type

Observational

Enrollment (Actual)

20

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Morocco
      • Oujda, Morocco, 60000
        • Oujda

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Twenty patients were included in the study: 11 women (55%) and 9 men (45%). The mean age at diagnosis was 63.1 ± 22.3 years (range, 16-90 years).

Regarding skin phototype, 5 patients (25%) had Fitzpatrick phototype II, 9 patients (45%) had phototype III, and 6 patients (30%) had phototype IV [4]. Most patients reported substantial lifetime sun exposure, often related to outdoor occupational activities such as farming or security work. Overall, chronic sun exposure was identified in 18 patients (90%).The remaining two patients (10%) had limited cumulative sun exposure due to their young age; however, they remained highly susceptible to UV radiation because of a history of xeroderma pigmentosum.

Actinic keratosis was noted in one patient (5%), a history of eyelid trauma in one patient (5%), and chronic tobacco use in two patients (10%), both of whom were male. Xeroderma pigmentosum was present in two patients (10%). No history of arsenic exposure or prior radiotherapy was documented in

Description

Inclusion Criteria:

  • all patient with carcinoma

Exclusion Criteria:

  • no exclusion criteria

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
carcinomas
patient with carcinomas

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Eyelid carcinomas
Time Frame: from January 2023 to December 2025
from January 2023 to December 2025

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Mohammed VI University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2023

Primary Completion (Actual)

January 1, 2026

Study Completion (Actual)

June 1, 2026

Study Registration Dates

First Submitted

July 19, 2026

First Submitted That Met QC Criteria

July 19, 2026

First Posted (Actual)

July 23, 2026

Study Record Updates

Last Update Posted (Actual)

July 23, 2026

Last Update Submitted That Met QC Criteria

July 19, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • soufiane

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Carcinomas (Including Squamous Cell and Adenocarcinoma)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe